Apimeds Pharmaceuticals US (APUS) Interest & Investment Income (2024 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Interest & Investment Income for 3 consecutive years, with $21764.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Interest & Investment Income rose 42.74% year-over-year to $21764.0; the trailing twelve-month figure through Jun 2026 stood at $129356.0 (up 740.19% YoY), and the FY2025 full-year result was $107595.0, up 3710.02% from the prior year.
• Interest & Investment Income retreated to $21764.0 in Q2 2026 per APUS's latest filing, from $35919.0 in the prior quarter.
• Across five years, Interest & Investment Income topped out at $56426.0 in Q3 2025 and bottomed at $3.0 in Q1 2025.
• Historically, Interest & Investment Income has averaged $14687.0 across 3 years, with a median of $2161.0 in 2024.
• The widest YoY moves for Interest & Investment Income: up 119630.0% in 2025, down 99.86% in 2025.
• Over 3 years, Interest & Investment Income stood at $30.0 in 2024, then soared by 119630.0% to $35919.0 in 2025, then plunged by 39.41% to $21764.0 in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $21764.0, $35919.0, and $56426.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.